aTyr Pharma, Inc. (NASDAQ:ATYR) Receives $25.67 Consensus Target Price from Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has received a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $25.6667.

A number of research analysts recently weighed in on ATYR shares. Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th. Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of aTyr Pharma in a research note on Monday, December 29th.

aTyr Pharma Stock Performance

Shares of ATYR opened at $0.79 on Friday. aTyr Pharma has a fifty-two week low of $0.64 and a fifty-two week high of $7.29. The firm’s 50-day simple moving average is $0.87 and its two-hundred day simple moving average is $0.83. The stock has a market cap of $77.63 million, a PE ratio of -1.00 and a beta of 0.64.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Thursday, March 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. Equities research analysts predict that aTyr Pharma will post -0.59 EPS for the current year.

Institutional Trading of aTyr Pharma

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in aTyr Pharma during the 4th quarter valued at about $62,000. ADAR1 Capital Management LLC raised its holdings in aTyr Pharma by 35.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after buying an additional 13,385 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of aTyr Pharma in the fourth quarter worth approximately $603,000. Deutsche Bank AG lifted its stake in shares of aTyr Pharma by 3,779.5% in the fourth quarter. Deutsche Bank AG now owns 120,341 shares of the company’s stock worth $94,000 after buying an additional 117,239 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of aTyr Pharma by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock valued at $1,789,000 after buying an additional 105,514 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.